Market Place
Sourcing Support
Reviva to Present Brilaroxazine Speech Data at CNS Summit 2024
06 Nov 2024 //
GLOBENEWSWIRE
Reviva Pharmaceuticals To Participate In Lytham Conference
26 Sep 2024 //
GLOBENEWSWIRE
Reviva Announces New Vocal Biomarker Data
09 Sep 2024 //
GLOBENEWSWIRE
Reviva To Join H.C. Wainwright Investment Conference
04 Sep 2024 //
GLOBENEWSWIRE
Reviva To Host KOL Event On Brilaroxazine Vocal Biomarker Data
27 Aug 2024 //
GLOBENEWSWIRE
Reviva Gets US Patent For Brilaroxazine In Pulmonary Fibrosis
06 Aug 2024 //
GLOBENEWSWIRE
Reviva Gets European Patent For Brilaroxazine In Pulmonary Hypertension
09 Jul 2024 //
GLOBENEWSWIRE
Reviva Provides Enrollment Update For Brilaroxazine
15 May 2024 //
GLOBENEWSWIRE
Reviva Reports Q1 2024 Results, Business Highlights
14 May 2024 //
GLOBENEWSWIRE
Reviva To Present Brilaroxazine Efficacy Data In IPF At ATS 2024
13 May 2024 //
GLOBENEWSWIRE
Reviva Brilaroxazine Preclinical Data At ASPET 2024
09 May 2024 //
GLOBENEWSWIRE
Reviva Gets FDA Alignment On Brilaroxazine NDA Trials
15 Apr 2024 //
GLOBENEWSWIRE
Reviva to Present Ph 3 Data for Brilaroxazine in Schizophrenia at the Meeting
28 Mar 2024 //
GLOBENEWSWIRE
Reviva to Host KOL Event to Discuss Topline Data from Phase 3 of Brilaroxazine
06 Feb 2024 //
GLOBENEWSWIRE
Reviva Pharma`s schizophrenia drug succeeds in late-stage study
31 Oct 2023 //
HEALTH ET
Reviva Announces Last Patient Evaluated in Phase 3 Trial for Brilaroxazine
25 Sep 2023 //
GLOBENEWSWIRE
Reviva Announces Enrollment Completion for Phase 3 Study for Brilaroxazine
17 Aug 2023 //
GLOBENEWSWIRE
Reviva Announces 80% Global Enrollment for Pivotal Ph3 RECOVER Brilaroxazine
22 Jun 2023 //
GLOBENEWSWIRE
Reviva Announces Presentation of Data on Brilaroxazine at the ASPET
22 May 2023 //
GLOBENEWSWIRE
Reviva Announces Intent to File an IND for Brilaroxazine in Psoriasis
11 May 2023 //
GLOBENEWSWIRE
Reviva Presented Preclinical Data on Novel Serotonin-Dopamine Brilaroxazine
01 May 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine
25 Apr 2023 //
GLOBENEWSWIRE
Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Brilaroxazine
20 Apr 2023 //
GLOBENEWSWIRE
Reviva Announces Enrollment Update for Phase 3 Study Evaluating Brilaroxazine
31 Oct 2022 //
GLOBENEWSWIRE
Reviva Pharma Reports Second Quarter 2022 Financial Results
15 Aug 2022 //
GLOBENEWSWIRE
Reviva to Host Key Opinion Leader Webinar on Brilaroxazine
25 Apr 2022 //
GLOBENEWSWIRE
Reviva Pharma Begins Dosing in Pivotal Phase 3 Study Evaluating Brilaroxazine
01 Feb 2022 //
GLOBENEWSWIRE
Reviva Pharma Bags FDA MPL for Phase 3 Trial of Brilaroxazine in Schizophrenia
10 Jan 2022 //
GLOBENEWSWIRE
